The Surgeon
Volume 8, Issue 5 , Pages 239-246 , October 2010

Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer

Received 8 February 2010 ,Revised 1 March 2010 ,Accepted 4 March 2010.

References 

  1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(Suppl. 1):171–190
  2. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82(1):111–115
  3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66
  4. Perini MV, Montagnini AL, Jukemura J, Penteado S, Abdo EE, Patzina R, et al. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford). 2008;10(5):356–362
  5. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg. 2008;247(3):456–462
  6. Ozawa F, Friess H, Kunzli B, Shrikhande SV, Otani T, Makuuchi M, et al. Treatment of pancreatic cancer: the role of surgery. Dig Dis. 2001;19(1):47–56
  7. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–15
  8. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27(3):324–329
  9. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish cancer registry. Gut. 2005;54(3):385–387
  10. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586–594
  11. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg. 2006;93(6):662–673
  12. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French association of surgery. Br J Surg. 1994;81(1):102–107
  13. Janes RH, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, et al. National patterns of care for pancreatic cancer. Results of a survey by the commission on cancer. Ann Surg. 1996;223(3):261–272
  14. Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg. 1999;36(2):59–152
  15. Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’Graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003;138(12):1310–1314discussion 1315
  16. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413
  17. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–1210
  18. Murr MM, Sarr MG, Oishi AJ, van Heerden JA. Pancreatic cancer. CA Cancer J Clin. 1994;44(5):304–318
  19. Berrino FCR, Estève J, Gatta G, Hakulinen T, Micheli A, Saint M, et al., editors. Survival of cancer patients in Europe: the EUROCARE-2 study. 2000/01/05; 1999.
  20. Fernandez E, La Vecchia C, Porta M, Negri E, Lucchini F, Levi F. Trends in pancreatic cancer mortality in Europe, 1955–1989. Int J Cancer. 1994;57(6):786–792
  21. Department of Health . Referral guidelines for suspected cancer. Available at: 2000;www.doh.gov.uk/pub/docs/doh/guidelines.pdf
  22. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353(11):1105–1113
  23. Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15(1):21–33
  24. Schussele Filliettaz S, Juillerat P, Burnand B, Arditi C, Windsor A, Beglinger C, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy. 2009;41(3):218–226
  25. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328
  26. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319
  27. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The international prostate cancer screening trial evaluation group. J Med Screen. 1996;3(2):97–104
  28. Gotzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jorgensen KJ. Breast screening: the facts – or maybe not. BMJ. 2009;338:b86
  29. McDermott F, Hughes E, Pihl E, Milne BJ, Price A. Symptom duration and survival prospects in carcinoma of the rectum. Surg Gynecol Obstet. 1981;153(3):321–326
  30. Bharucha S, Hughes S, Kenyon V, Anderson ID, Carlson GL, Scott NA. Targets and elective colorectal cancer: outcome and symptom delay at surgical resection. Colorectal Dis. 2005;7(2):169–171
  31. Gonzalez-Hermoso F, Perez-Palma J, Marchena-Gomez J, Lorenzo-Rocha N, Medina-Arana V. Can early diagnosis of symptomatic colorectal cancer improve the prognosis?. World J Surg. 2004;28(7):716–720
  32. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999;79(5–6):858–864
  33. Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet. 1999;353(9159):1132–1135
  34. Quarterman RL, McMillan A, Ratcliffe MB, Block MI. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;125(1):108–113discussion 113–4
  35. Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Stahle E. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax. 2004;59(1):45–49
  36. Kirwan JM, Tincello DG, Herod JJ, Frost O, Kingston RE. Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit. BMJ. 2002;324(7330):148–151
  37. Crawford SC, Davis JA, Siddiqui NA, de Caestecker L, Gillis CR, Hole D, et al. The waiting time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland. BMJ. 2002;325(7357):196
  38. Windham TC, Termuhlen PM, Ajani JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol. 2002;81(3):118–124discussion 124–5
  39. Maconi G, Kurihara H, Panizzo V, Russo A, Cristaldi M, Marrelli D, et al. Gastric cancer in young patients with no alarm symptoms: focus on delay in diagnosis, stage of neoplasm and survival. Scand J Gastroenterol. 2003;38(12):1249–1255
  40. Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H. Reasonable delay of surgical treatment in men with localized prostate cancer – impact on prognosis?. Eur Urol. 2005;47(6):756–760
  41. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol. 2004;172(5 Pt 1):1835–1839
  42. Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg. 2004;187(5):575–579
  43. Goyal S, Roscoe J, Ryder WD, Gattamaneni HR, Eden TO. Symptom interval in young people with bone cancer. Eur J Cancer. 2004;40(15):2280–2286
  44. Halperin EC, Watson DM, George SL. Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer. 2001;91(8):1444–1450
  45. Bacci G, Ferrari S, Longhi A, Mellano D, Giacomini S, Forni C. Delay in diagnosis of high-grade osteosarcoma of the extremities. Has it any effect on the stage of disease?. Tumori. 2000;86(3):204–206
  46. Bennett DR, Wasson D, MacArthur JD, McMillen MA. The effect of misdiagnosis and delay in diagnosis on clinical outcome in melanomas of the foot. J Am Coll Surg. 1994;179(3):279–284
  47. Office for National Statistics . Cancer survival: cancer survival trends by period of diagnosis and sex age-standardised relative survival at one and five years, and average increase in relative survival between successive five-year periods of diagnosis, 1971–1990. Available at: 2009;http://www.statistics.gov.uk/StatBase/xsdataset.asp?More=Y&vlnk=982&All=Y&B2.x=58&B2.y=19.2009
  48. Yamaguchi K, Nishihara K, Tsuneyoshi M. Non-icteric pancreas head carcinoma fares worse than icteric pancreas head carcinoma. J Surg Oncol. 1992;49(4):253–258
  49. Gilliam AD, Lobo DN, Rowlands BJ, Beckingham IJ. The ‘two-week’ target for the diagnosis of pancreatic carcinoma: an achievable aim?. Eur J Surg Oncol. 2003;29(7):575–579

PII: S1479-666X(10)00101-0

doi: 10.1016/j.surge.2010.03.001

The Surgeon
Volume 8, Issue 5 , Pages 239-246 , October 2010

Article Tools

* Image Usage & Resolution